FDA Clears Celsion to Initiate Clinical Trials for the Use of ThermoDox with RFA in the Treatment of Liver Cancer COLUMBIA, Md.--(BUSINESS WIRE)--Aug. 31, 2004--CELSION CORPORATION (AMEX:CLN) today announced that the Food and Drug Administration (FDA) will allow the human clinical trial for its

Celsion Submits Response to FDA Warning Letter Columbia, MD - June 1, 2004: CELSION CORPORATION (AMEX: CLN) announced today that its response to the warning letter issued to it by the Food and Drug Administration (FDA) on May 7, 2004 was submitted to the FDA on Friday, May 28, 2004.

Celsion Demands Immediate End To Unauthorized Trading On Berlin-Bremen Stock Exchange Columbia, MD - May 28, 2004: CELSION CORPORATION (AMEX: CLN) announced today that it has learned that its common stock has been listed on the Berlin-Bremen Stock Exchange without the Company's prior knowledge,

Celsion Clarifies FDA Warning Letter COLUMBIA, MD - May 25, 2004: CELSION CORPORATION (AMEX: CLN) announced today that it has received a warning letter from the Food and Drug Administration (the FDA) regarding the Phase I and Phase II clinical trials of its Prolieve™ Thermodilatation system for the

Celsion to Hold Annual Meeting: Shareholders may Participate By Telephone Or Webcast Celsion to Hold Annual Meeting: Shareholders may Participate By Telephone Or Webcast Columbia, MD - May 21, 2004: CELSION CORPORATION (AMEX: CLN) will hold its annual meeting on Tuesday, May 25, 2004 at 10:15 a.m.